Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M561Revenue $M277Net Margin (%)1.5Z-Score2.2
Enterprise Value $M666EPS $-0.1Operating Margin %3.8F-Score4
P/E(ttm))147Cash Flow Per Share $0.7Pre-tax Margin (%)0.2Higher ROA y-yN
Price/Book2.310-y EBITDA Growth Rate %0Quick Ratio1.9Cash flow > EarningsY
Price/Sales2.15-y EBITDA Growth Rate %0Current Ratio2.9Lower Leverage y-yN
Price/Cash Flow7.4y-y EBITDA Growth Rate %-23.1ROA % (ttm)0.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)1.6Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M32.6ROI % (ttm)1.7Gross Margin Increase y-yN

Gurus Latest Trades with AMRI

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMRIJoel Greenblatt 2014-09-30 Sold Out -0.03%$18.7 - $22.89
($20.45)
$ 17.19-16%Sold Out0
AMRIJoel Greenblatt 2014-06-30 Reduce-0.03%$14.63 - $19.89
($16.89)
$ 17.192%Reduce -47.95%102,934
AMRIGeorge Soros 2014-06-30 Sold Out -0.01%$14.63 - $19.89
($16.89)
$ 17.192%Sold Out0
AMRIGeorge Soros 2014-03-31 Buy 0.01%$10.08 - $19.91
($13.57)
$ 17.1927%New holding, 48700 sh.48,700
AMRIJoel Greenblatt 2013-09-30 Buy 0.1%$10.81 - $13.72
($12.29)
$ 17.1940%New holding, 228216 sh.228,216
AMRIJohn Rogers 2013-03-31 Sold Out -0.04%$5.28 - $10.84
($7.56)
$ 17.19127%Sold Out0
AMRIJohn Rogers 2012-12-31 Reduce-0.01%$3.45 - $5.5
($4.25)
$ 17.19304%Reduce -27.34%372,844
AMRIJohn Rogers 2012-06-30 Buy 0.03%$2.32 - $3.22
($2.81)
$ 17.19512%New holding, 473769 sh.473,769
AMRIJean-Marie Eveillard 2010-12-31 Sold Out $5.05 - $6.93
($5.92)
$ 17.19190%Sold Out0
AMRIJean-Marie Eveillard 2010-06-30 Buy $5.1 - $8.86
($7.07)
$ 17.19143%New holding, 10000 sh.10,000
AMRIGeorge Soros 2007-12-31 Sold Out -0.01%$11.98 - $18.2
($14.8)
$ 17.1916%Sold Out0
AMRIGeorge Soros 2007-09-30 Buy 0.01%$13.59 - $16.48
($15)
$ 17.1915%New holding, 14780 sh.14,780
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMRI is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


AMRI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Nolan Michael MCFO 2015-02-25Sell5,000$16.171.67view
Hagen Steven RSVP Pharmaceutical Dev & Mfg 2015-02-23Sell3,750$16.221.36view
Hagen Steven RSVP Pharmaceutical Dev & Mfg 2015-02-18Sell6,623$16.54-0.6view
D AMBRA THOMAS E PHDDirector 2015-02-10Sell20,000$16.91-2.78view
D AMBRA CONSTANCE M10% Owner 2015-02-10Sell20,000$16.91-2.78view
CABLE STUART M10% Owner 2015-02-02Sell30,000$16.320.74view
D AMBRA THOMAS E PHDDirector 2015-01-12Sell20,000$16.45-0.06view
D AMBRA CONSTANCE M10% Owner 2015-01-12Sell20,000$16.45-0.06view
CABLE STUART M10% Owner 2015-01-07Sell7,694$162.75view
CABLE STUART M10% Owner 2015-01-05Sell22,306$16.211.42view

Press Releases about AMRI :

    Quarterly/Annual Reports about AMRI:

    News about AMRI:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 
    View on AMRI Jun 27 2010 
    AMRI Announces Second Quarter 2009 Results Aug 04 2009 
    AMRI Announces Fourth Quarter 2008 Results Feb 09 2009 
    AMRI Names Senior Director, Analytical and Quality Services Jan 12 2009 

    More From Other Websites
    AMRI to Present at Barclays Global Healthcare Conference Feb 25 2015
    AMRI to Present at Barclays Global Healthcare Conference Feb 25 2015
    Stocks From Leading Industries Feb 21 2015
    ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets Feb 17 2015
    ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 13 2015
    ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 12 2015
    Albany Molecular Research posts 4Q loss Feb 12 2015
    Albany Molecular Research posts 4Q loss Feb 12 2015
    AMRI Announces Fourth Quarter and Full Year 2014 Results Feb 12 2015
    Q4 2014 Albany Molecular Research Inc Earnings Release - Before Market Open Feb 12 2015
    AMRI to Announce Fourth Quarter and Full Year Results Jan 29 2015
    Drug developer receives $37 million federal research contract Jan 20 2015
    AMRI Receives NIH Contract Award for the Formulation Development and Manufacture of Pre-Clinical and... Jan 19 2015
    ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 15 2015
    New York drug developer pays $60 million for U.K. and Indiana businesses Jan 15 2015
    AMRI Announces Agreement with Genovi Pharmaceuticals Limited for Development and Manufacturing of... Jan 12 2015
    AMRI Announces CFO Transition Jan 12 2015
    DEADLINE MONDAY: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Albany Molecular... Jan 09 2015
    Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against... Jan 09 2015
    Aptuit to Divest Two Non-Core Sites; Facilitates Reinvestment and Accelerated Growth in Core Area of... Jan 09 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK